Free Trial

Alaunos Therapeutics Q4 2022 Earnings Report

Alaunos Therapeutics logo
$1.76 -0.04 (-1.94%)
As of 01/21/2025 03:59 PM Eastern

Alaunos Therapeutics EPS Results

Actual EPS
-$6.00
Consensus EPS
-$13.50
Beat/Miss
Beat by +$7.50
One Year Ago EPS
N/A

Alaunos Therapeutics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alaunos Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Alaunos Therapeutics Earnings Headlines

Please take this warning seriously...
I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as January 29th… Meaning you don’t have much time to prepare.
See More Alaunos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alaunos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alaunos Therapeutics and other key companies, straight to your email.

About Alaunos Therapeutics

Alaunos Therapeutics (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

View Alaunos Therapeutics Profile

More Earnings Resources from MarketBeat